On Wednesday, Following Stocks were among the “Top Gainers” of U.S. Stock Market: Trillium Therapeutics, (NASDAQ:TRIL), ARCA biopharma, (NASDAQ:ABIO), Oi S.A., (NYSE:OIBR), Harmony Gold Mining Company, (NYSE:HMY)
Trillium Therapeutics, (NASDAQ:TRIL), with shares gained 20.37%, closed at $24.35, hitting new 52-week high of $25.57.
ARCA biopharma, (NASDAQ:ABIO), with shares jumped 17.80%, settled at $0.93.
Oi S.A., (NYSE:OIBR), with shares climbed 20.13%, and closed at $1.85.
Harmony Gold Mining Company, (NYSE:HMY), gained 14.37%, and closed at $1.99.
Latest NEWS regarding these Stocks are depicted underneath:
Trillium Therapeutics Inc. (NASDAQ:TRIL)
Trillium Therapeutics Inc. (TRIL), declared that it has priced an underwritten public offering of 1,522,395 ordinary shares and 1,077,605 non-voting convertible preferred shares at a price of US$19.50 per share for aggregate gross proceeds of US$50.7 million before deducting underwriting discounts and commissions and other offering expenses.
Trillium has also granted the underwriters a 30-day option to purchase up to an additional 228,359 ordinary shares, which, if exercised, would result in additional gross proceeds of about US$4.45 million. The offering is predictable to close on or about April 7, 2015, subject to the satisfaction of customary closing conditions.
All of the shares in the offering are to be sold by Trillium, with net proceeds to be used to develop product candidates in addition to for working capital and general corporate purposes.
Leerink Partners LLC and Cowen and Corporation, LLC are acting as joint book-runners for the offering. Oppenheimer & Co. Inc. is acting as co-manager in the offering.
Trillium Therapeutics Inc., an immuno-oncology corporation, develops therapies for the treatment of cancer. Its primary program is SIRPaFc, an antibody-like fusion protein, which blocks the activity of CD47, a molecule that allows tumor cells to escape destruction by the immune system.
ARCA biopharma, Inc. (NASDAQ:ABIO)
Formerly on March 16, ARCA biopharma, Inc. (ABIO), offered an update on GENETIC-AF, the Corporation’s Phase 2B/3 clinical trial evaluating Gencaro (bucindolol hydrochloride) as a potential treatment for atrial fibrillation (AF).
ARCA was founded on the belief that a personalized medicine approach to drug development, tailoring medical treatment to the individual genetic characteristics of each patient, can enable more effective therapies, improve patient outcomes and reduce healthcare costs. ARCA’s lead development program is intended to be a direct implementation of those ideas. Gencaro is being developed as a potential treatment for AF. ARCA has identified ordinary genetic variations that it believes may predict individual patient response to Gencaro, giving it the potential to be the first genetically-targeted AF prevention treatment. AF is considered an epidemic cardiovascular disease with an estimated prevalence of at least 2.7 million Americans in 2010.
ARCA biopharma, Inc., a biopharmaceutical corporation, focuses on developing genetically-targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacologically unique beta-blocker and mild vasodilator for the treatment of atrial fibrillation in patients with heart failure and left ventricular dysfunction. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.
Oi S.A. (NYSE:OIBR)
Oi S.A. (OIBR), following art. 157, paragraph 4, of Law No. 6,404/76 and Instruction No. 358/02 of the Brazilian Securities and Exchange Commission (Comissao de Valores Mobiliarios – CVM), and in furtherance with the Material Fact published on March 26, 2015, informs its shareholders and the market in general, that on this date, Telemar Participacoes S.A. revealed the following Material Fact.
The shareholders of TmarPart unanimously approved the adoption of an alternative share structure, after analyzing options and taking into consideration the current obstacles to a registration of TmarPart shares with the U.S. Securities and Exchange Commission that would be necessary to allow the incorporacao de acoes of Oi and TmarPart, as described in the Material Fact of March 26, 2015. The adopted alternative share structure allows the main aims of the Transaction to be met, with Oi able to adopt the corporate governance best practices prescribed by the regulations of the Novo Mercado segment of the BM&F Bovespa S.A. – Bolsa de Valores, Mercadorias e Futuros and disperse its voting rights, keeping in mind the final objective of opportunely concluding the Transaction with the result of listing the shares presently held by Oi shareholders, and, at a later point, those of the shares held by PT SGPS, on the Novo Mercado.
Oi S.A., through its auxiliaries, provides integrated telecommunication services for residential customers, companies, and governmental agencies in Brazil. It operates in three segments: Fixed-Line and Data Transmission Services, Mobile Services, and Other Services.
Harmony Gold Mining Company Limited (NYSE:HMY)
Harmony Gold Mining Company Limited (HMY), holds the market capitalization of $870.63M. For the last twelve months, the stock was able to keep return on equity at -4.90%, while return on assets at -3.70%, in response to its return on investment at -3.70%. Its 20-day moving average gained 6.82%, below 50-day moving average of -16.77%, below 200-day moving average of -17.65% from the latest market price of $1.99. The mean recommendation of analysts for this stock is 3.00.(where 1=Buy, 5=Sale).
Harmony Gold Mining Corporation Limited is engaged in the exploration and mining of gold in South Africa and Papua New Guinea. The corporation also explores for silver, copper, and molybdenum.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
